

A person in a white lab coat is holding a small, white, handheld medical device. The device has a small screen and several buttons, including a 'START' button. The background is a blurred clinical setting.

MDR from a small company's perspective

To stay in MDD or early transition to MDR
– Zenicors perspective and strategy.




富嶽三十六景 神奈川沖
浪裏

葛飾画

Zenikor Medical Systems AB

- Founded: 2003 (in Stockholm)
- Turnover: 21 million SEK
- 18 employees (12 within Sales & Marketing)
- Zenicor EKG-2 device, MDD class IIa (since 2010)
- Zenicor-EKG Back-end system, MDD class IIa (since 2004)



Gustav Lins

- Operations and Quality Manager at Zenicor
- Responsible for the Quality and Regulatory Affairs
- More than 10 years of experience from the Medtech industry both from small and large companies
- Global responsibility for Quality and Regulatory Affairs at Sectra, Philips, Swemac Imaging and Demetech.
- Gustav loves Medtech products






Major business risks associated choosing the road MDR “direct”

- Notified Body ready for MDR?
- Resources needed to create all MDR documentation?

Zenikor's MDD/MDR journey



Costs




Next step towards MDR for Zenicor

- Zenicor needs to transfer products to MDR before 2024.
- Limitations with regards to design changes since the products will remain within MDD.

Looking ahead

- Patient safety and clinical benefits will always be the main objective within the Medtech industry.
- Will Medtech products be safer within MDR than MDD?
- Will we create more patient benefits within MDR than MDD?
- Should we expect that regulatory submissions to CA and NB will become longer, more expensive and less predictable?
- Will more small companies "disappear" into the large "Dragons"?
- Will there be more obstacles for a small company to enter the Medtech industry due to MDR?



Gustav Lins
Operations Manager
gustav.lins@zenikor.se